Table 1.
Patients, disease, and transplant characteristics
| Variable | Haplo (n = 336) | MSD (n = 869) | P |
|---|---|---|---|
| Patient age, y | <.001 | ||
| 18-54 | 152 (45) | 542 (62) | |
| ≥55 | 184 (55) | 327 (38) | |
| Median (range) | 57 (18-74) | 52 (18-71) | |
| Donor age, y | <.001 | ||
| 18-54 | 212 (63) | 560 (64) | |
| ≥55 | 37 (11) | 306 (35) | |
| Missing | 87 (26) | 3 (<1) | |
| Median (range) | 39 (16-68) | 51 (18-73) | |
| Sex | .42 | ||
| Male | 183 (54) | 451 (52) | |
| Female | 153 (46) | 418 (48) | |
| Race | <.001 | ||
| White | 229 (68) | 727 (84) | |
| African American | 69 (21) | 46 (5) | |
| Others | 20 (6) | 70 (8) | |
| Missing | 18 (5) | 26 (3) | |
| HCT-CI | .20 | ||
| 0 | 99 (29) | 254 (29) | |
| 1 | 53 (16) | 136 (16) | |
| 2 | 43 (13) | 124 (14) | |
| ≥3 | 133 (40) | 309 (36) | |
| Missing | 8 (2) | 46 (5) | |
| Karnofsky performance status | .78 | ||
| <90 | 112 (33) | 308 (35) | |
| ≥90 | 208 (62) | 551 (64) | |
| Missing | 16 (5) | 10 (1) | |
| Time from diagnosis to HCT, mo | <.001 | ||
| <6 | 231 (69) | 721 (83) | |
| 6-12 | 89 (26) | 131 (15) | |
| >12 | 16 (5) | 17 (2) | |
| Median (range) | 5 (2-36) | 4 (1-18) | |
| Type of AML | .05 | ||
| De novo | 244 (73) | 662 (76) | |
| Transformed from MDS/MPN | 70 (21) | 133 (15) | |
| Therapy related | 22 (6) | 74 (9) | |
| Donor/recipient cytomegalovirus serostatus | .26 | ||
| +/+ | 139 (41) | 328 (38) | |
| +/− | 29 (9) | 98 (11) | |
| −/+ | 91 (27) | 223 (26) | |
| −/− | 75 (22) | 204 (23) | |
| Missing | 2 (<1) | 16 (2) | |
| Donor/recipient sex | .47 | ||
| Male-male | 114 (34) | 256 (29) | |
| Male-female | 88 (26) | 231 (26) | |
| Female-male | 69 (21) | 195 (23) | |
| Female-female | 65 (19) | 187 (22) | |
| Cytogenetics | <.001 | ||
| Favorable | 12 (4) | 26 (3) | |
| Intermediate | 170 (50) | 560 (64) | |
| Poor: monosomal karyotype | 33 (10) | 76 (9) | |
| Poor: other | 70 (21) | 174 (20) | |
| Not tested or missing | 51 (15) | 33 (4) | |
| MRD prior to HCT | .10 | ||
| Negative | 250 (74) | 598 (62) | |
| Positive | 66 (20) | 192 (29) | |
| Missing | 20 (6) | 79 (9) | |
| Conditioning intensity | <.001 | ||
| MAC with TBI | 34 (10) | 216 (24) | |
| MAC without TBI | 83 (25) | 396 (45) | |
| RIC/nonmyeloablative | 219 (65) | 250 (30) | |
| Missing | 0 | 7 (<1) | |
| Graft source | <.001 | ||
| Bone marrow | 208 (62) | 56 (7) | |
| Peripheral blood | 128 (38) | 813 (93) | |
| GVHD prophylaxis* | <.001 | ||
| CNI + methotrexate ± others | 3 (<1) | 622 (70) | |
| CNI + mycophenolate mofetil ± others | 322 (96) | 154 (19) | |
| Others | 9 (3) | 88 (11) | |
| Missing | 2 (<1) | 5 (<1) | |
| Year of HCT | <.001 | ||
| 2008-2010 | 36 (11) | 424 (49) | |
| 2011-2015 | 300 (89) | 445 (51) | |
| Median follow-up of survivors (range), mo | 35 (3-97) | 60 (3-119) |
Unless otherwise noted, all data are n (%).
Haplo, haploidentical; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
*
All Haplo-HCT patients received PT-Cy, whereas all MSD patients received a CNI.